



Date: 5<sup>th</sup> February, 2026

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir/Madam,

**Sub: Investors Presentation on Unaudited Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2025**

Please find enclosed the Investors Presentation on Unaudited Financial Results of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2025.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**

Encl.: A/a.

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123



# **Alembic Pharmaceuticals Ltd.**

## **Investor Call Info. Supplement**

**Q3FY26**



# International Business Unit

# International Generics – Region wise sales summary (Q3'26)

(Rs Crs.)

Region	Q3	Q3	Growth Q3	Q2	Growth Seq. Qtr
	FY'25	FY'26		FY'26	
USA - Direct	445	478	7%	467	2%
USA - Other	61	66	8%	80	-17%
Export Incentive and Other income & PLI	14	9	-36%	20	-53%
<b>USA</b>	<b>521</b>	<b>553</b>	<b>6%</b>	<b>567</b>	<b>-2%</b>
Canada	71	93	32%	66	40%
Australia	62	103	65%	104	-1%
Europe & ROW	154	198	28%	203	-2%
Export Incentive and Other income & PLI	8	7	-18%	13	-50%
<b>EROW</b>	<b>295</b>	<b>401</b>	<b>36%</b>	<b>387</b>	<b>4%</b>
<b>Total</b>	<b>816</b>	<b>954</b>	<b>17%</b>	<b>954</b>	<b>0%</b>

## Q3 FY 26 vs Q3 FY 25 growth /de-growth :

- USA Direct growth on account of: Sacu+Valsartan 14.6 vs Nil (14.6 Cr), Ticagrelor FDF 8.6 vs Nil (8.6 Cr)  
Metoprolol FDF 15.0 vs 6.9 (8.1 Cr)  
Degrowth on account of: Formoterol 2.5 vs 13.2 (10.7 Cr), Timolol Opth 2.6 vs 10.9 (8.3 Cr)  
Valsartan+Amlodipine FDF : 6.5 vs 11.2 Cr (4.7 Cr)
- Australia growth Telmi+Amlo FDF 20.0 vs Nil (20.0 Cr); Degrowth on account of: Duloxetine 13.9 vs 15.1 (1.2 Cr)
- Canada growth Duloxetine 33.8 vs 28.3 (5.6 Cr); Degrowth on account of: Pregabalin FDF 3.5 vs 8.0 (4.5 Cr)
- Europe & ROW growth on account of Bupropion 32.4 vs 11.3 (21.1 Cr); Degrowth on account of: Duloxetine (INCL PEL) 4.1vs 14.4 (10.3 Cr)

# International Generics – Region wise sales summary (YTD Dec'25)

(Rs Crs.)

Region	YTD DEC'24	YTD DEC'25	Growth
USA - Direct	1,220	1,408	15%
USA - Other	198	200	1%
Export Incentive and Other income & PLI	31	35	15%
<b>USA</b>	<b>1,449</b>	<b>1,643</b>	<b>13%</b>
Canada	236	211	-11%
Australia	187	307	65%
Europe & Others	411	569	38%
Export Incentive and Other income & PLI	18	24	33%
<b>EROW</b>	<b>852</b>	<b>1,111</b>	<b>30%</b>
<b>Total</b>	<b>2,301</b>	<b>2,754</b>	<b>20%</b>

## YTD Dec'25 vs YTD Dec'24 growth /de-growth :

- USA Direct growth on account of: Dabigatran 90.0 vs 30.3 (59.7 Cr), Sacu+Valsartan 53.9 vs Nil (53.9Cr)  
Ivabradine 24.8 vs Nil (24.8 Cr)  
Degrowth on account of: Formoterol: 20.4 vs 39.6 Cr (19.1 Cr), Timolol Ophth: 10.8 vs 25.0 Cr (14.2 Cr), Diclo Top Sol: 8.6 vs 21.8 Cr (13.2 Cr)
- Australia growth Telmi+Amlo 20.5 vs Nil(20.5 Cr); Degrowth on account of: Cande+HCTZ 5.9 vs 6.7 (0.8 Cr)
- Canada growth Dapagliflozin 13.6 vs 6.0 (7.6 Cr); Degrowth on account of: Duloxetine 60.9 vs 89.9 (28.9 Cr)
- Europe & ROW growth on account of Bupropion FDF 77.7 vs 44.3 (33.4 Cr); Degrowth on account of: Celecoxib 5.9 vs 14.4 (8.5 Cr)

Region	Q3	Q3	Growth Q3	Q2	Growth Seq. Qtr
	FY'25	FY'26		FY'26	
Europe	42	49	17%	64	-24%
Japan	9	5	-46%	27	-83%
Turkey	8	13	64%	11	18%
USA / Canada	24	14	-39%	20	-27%
Middle East	27	31	14%	25	21%
Latin America	35	44	27%	45	-1%
Asia Pacific	31	30	-3%	28	8%
Domestic / Dom. Reg	40	36	-11%	48	-25%
Vipul Gandhi - (Algeria & Europe)	0	-	-100%	0	
<b>Outside Sales Total</b>	<b>215</b>	<b>222</b>	<b>3%</b>	<b>268</b>	<b>-17%</b>
Pfizer	3	23	708%	13	84%
<b>Outside Sales with Pfizer</b>	<b>218</b>	<b>245</b>	<b>12%</b>	<b>281</b>	<b>-13%</b>
Export Incentive & Other Income	20	18	-9%	18	2%
PLI Income	21	-	-100%	15	-100%
<b>API Total</b>	<b>259</b>	<b>263</b>	<b>2%</b>	<b>314</b>	<b>-16%</b>

### Major Positives :-

- Azithromycin (incl Pfizer) 42.5 Vs 23.2 (19.2 Cr), Leflunomide : 12.4 Vs 4.7 (7.7 Cr), Lacosamide 11.1 Vs 4.9 (6.1 Cr)

### Major Negatives :-

- Mexiletine 4.9 Vs 13.5 (8.6 Cr), Ticagrelor Nil Vs 7.6 (7.6 Cr), Olmesartan Nil Vs 5.2 (5.2 Cr)

# API – Region wise sales Summary YTD Dec'25

(Rs. Crs)

Region	YTD Dec'24	YTD Dec'25	Growth
Europe	155	172	11%
Japan	53	48	-9%
Turkey	22	33	54%
USA / Canada	40	44	11%
Middle East	82	92	13%
Latin America	141	134	-5%
Asia Pacific	89	86	-4%
Domestic / Dom. Reg	112	112	0%
Vipul Gandhi - (Algeria & Europe)	1	0	-60%
<b>Outside Sales Total</b>	<b>694</b>	<b>721</b>	<b>4%</b>
Pfizer	15	47	213%
<b>Outside Sales with Pfizer</b>	<b>709</b>	<b>768</b>	<b>8%</b>
Export Incentive & Other Income	62	54	-13%
PLI Income	21	15	-27%
<b>API Total</b>	<b>791</b>	<b>837</b>	<b>6%</b>

### Major Positives :-

- Azithromycin (Incl Pfizer) : 120.1 Vs 74.0 (46.1 Cr), Vortioxetine 22.2 Vs 7.5 (14.8 Cr), Bosutinib 22.9 Vs 11.3 (11.6 Cr)

### Major Negatives :-

- O Desvenla 47.4 Vs 68.3 (20.8 Cr), Mexiletine 12.6 Vs 23.4 (10.8 Cr), Olmesartan 6.5 Vs 17.0 (10.5 Cr)

Time horizon / Category of product launch	No. of Products	Comments / Details
Upto FY'25	163	Alembic INC - 160 + 3 Partner (Partner includes Docosanol Cream launched by Cosette Pharma)
During Q1'26	4	Dorzo+Timo, Ticagrelor FDF, Rivaroxaban 2.5 Mg, Amlo+Atorva - FDF
During Q2'26	3	Sacubitril Valsartan, Icatibant Injection, Pantoprazole injection,
During Q3'26	2	PALIPERIDONE - FDF, TRETINOIN CRM 0.025%
Cumulative till FY'26	172	Alembic INC - 169 + 3 Partner (Partner includes Docosanol Cream launched by Cosette Pharma)
Planned Launch in Q4'26	7	Loteprednol & Tobramycin oph. Suspension, Dexlansoprazole DR capsules, Diltiazem HCl tablets, Sumatriptan inj, Doxorubicin Liposomal Inj. (DRL label), Phytonadione injectable emulsion (Sagent label), Dasatinib tablets

Filed during the year								
Product Name	Innovator Name	Innovator Brand	Type	Filing date	R&D at	Qtr	\$ Mn	Plant
Larotrectinib Capsules 25 mg and 100 mg	Bayer Health care Pharma INC	Vitrakvi	Para III,IV	6-May-25	ARC	Q1	82.0	F2
Digoxin Injection USP, 100 mcg (0.1 mg)/mL and 500 mcg (0.5 mg)/2 mL [250 mcg (0.25 mg)/mL]	COVIS PHARMA GMBH	LANOXIN & LANOXIN PEDIATRIC	Para I	30-Jun-25	Injectable	Q1	5.8	F3
Labetalol Hydrochloride Injection USP, 20mg/4mL (5mg/mL)	Hospira	Labetalol (RS)	Para I	31-Jul-25	Injectable	Q2	8.9	F3
Prednisolone Acetate Ophthalmic Suspension USP, 1%	Abbvie Inc	Pred forte	Para I	29-Sep-25	F-3 Ophthalmic	Q2	201.0	F3
Methylprednisolone Acetate Injectable Suspension, USP 40 mg/mL and 80mg/mL - Multi-Dose Vial	Pfizer	Depo Medrol	Para I	28-Nov-25	F-3 Injectables	Q3	33.6	F3
<b>Total Filed during the year</b>			<b>5</b>				<b>331.3</b>	

## Grid wise Filing Breakup - Since Inception

Dosage form Wise Allocation(Cumulative)				
Category	Filings	Final Approva	Tentative Approval	Pending Approval
OSD	175	141	15	19
Ophthalmic	27	20	2	5
Derma	35	30	1	4
Injectable	31	19	2	10
Inhalation	2	2	0	0
<b>Total</b>	<b>270</b>	<b>212</b>	<b>20</b>	<b>38</b>

# International Generics – ANDA filings and approval details

Category	No. Of ANDAs	Details
Filed upto end of FY25	266	• <b>91</b> Para I + <b>12</b> Para II + <b>32</b> Para III + <b>54</b> Para IV + <b>1</b> Para II,III,IV + <b>1</b> Para I,IV + <b>2</b> Para III,IV + <b>32</b> FTF+ <b>7</b> Orit + <b>34</b> Aleor
Filed during FY26	5	• <b>4</b> Para I + <b>1</b> Para III,IV
Withdrawn During FY26	1	• <b>1</b> FTF
Sold During FY26	0	
Cumulative Filed	270	• <b>95</b> Para I + <b>12</b> Para II + <b>32</b> Para III + <b>54</b> Para IV + <b>1</b> Para II,III,IV + <b>1</b> Para I,IV + <b>3</b> Para III,IV + <b>31</b> FTF+ <b>7</b> Orit + <b>34</b> Aleor
Final Approval upto end of FY25	194	• <b>67</b> Para I + <b>11</b> Para II + <b>28</b> Para III + <b>42</b> Para IV + <b>12</b> FTF + <b>6</b> Orit + <b>28</b> Aleor
Final Approvals during FY26	18	<ul style="list-style-type: none"> <li>• <b>Q1: 3</b> Para I + <b>1</b> Para IV + <b>2</b> FTF</li> <li><b>Q1-6 Approval :</b> 1) Carbamazepine tablets 200mg, 2) Bosutinib Tablets, 100 mg and 500 mg, 3) Ticagrelor Tablets (90 mg), 4) Rivaroxaban Tablets 2.5mg, 10 mg, 15 mg and 20 mg, 5) Amlodipine besylate and Atorvastatin calcium tablets USP, 6) Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL and 50 mg/.</li> <li>• <b>Q2: 3</b> Para I + <b>1</b> FTF + <b>1</b> Aleor</li> <li><b>Q2-5 Approvals :</b> 1) Carbamazepine Extended-Release Tablets USP, 100 mg, 200 mg and 400 mg, 2) Macitentan Tablets, 10 mg, 3) Tretinoin Cream USP,0.025%, 4) Phytonadione Injectable Emulsion USP 1mg/ 0.5 mL, 5) Paroxetine ER tablets</li> <li>• <b>Q3: 4</b> Para I + <b>1</b> Para II III IV + <b>2</b> Para IV</li> <li><b>Q3-7 Approvals :</b> 1)Triamcinolone Acetonide Injectable Suspension USP, 40 mg/mL 2)Diltiazem HCL tablets USP 30,60,90 120mg 3)Dexlansoprazole Delayed-Release Capsules, 30 mg and 60 mg 4) Dasatinib tablets 20,50,70,80,100 and 140mg 5)Sumatriptan injection USP,4mg/0.5ml, 6mg/0.5ml 6) Loteprednol etabonate and Tobramycin Ophthalmic Suspension, 0.5% &amp; 0.3% 7) Travoprost Ophthalmic Solution USP, 0.004% (Ionic buffer solution)</li> </ul>
ANDA Approved Sold During FY26	0	-
Cumulative Final Approval	212	• <b>77</b> Para I + <b>11</b> Para II + <b>28</b> Para III + <b>45</b> Para IV + <b>1</b> Para II III IV + <b>15</b> FTF + <b>6</b> Orit + <b>29</b> Aleor
Cumulative Tentative Approvals	20	

# International Generics – Pending approvals summary

Filing Type	0-1 Years	1-2 Years	2-3 Years	>3 Years	Total	IMS (USD Mil.)
PARA I	6	1	4	7	18	3,591
PARA II				1	1	178
PARA III			1	1	2	1,266
PARA IV		1	1	3	5	2,624
PARA II,III,IV					0	-
Para III & IV	3				3	4,241
Para I & IV	1				1	54
FTF				3	3	1,950
ORIT				1	1	5
ALEOR		1		3	4	221
<b>TOTAL</b>	<b>10</b>	<b>3</b>	<b>6</b>	<b>19</b>	<b>38</b>	<b>14,130</b>
IMS Market Size (USD Mil.)	4,631	224	1,217	8,058	14,130	14,130
TA Products						14,905

\*>3 years pending approvals: **1)** Fingolimod Capsules, **2)** Carfilzomib for Injection (AGH), **3)** Riociguat Tablets-0.5, 1, 1.5, 2 and 2.5 mg, **4)** Nizatidine Oral Suspension-150 MG/10 ML, **5)** Amitriptyline Hydrochloride Tablets USP 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg, **6)** Bumetanide Tablets USP 0.5/1/2mg, **7)** Dapsone Gel 5%, **8)** Haloperidol tablets 0.5mg,1 mg, 2 mg, 5mg, 10mg, 20mg, **9)** Venlafaxine ER tablets, **10)** Venetoclax tablets 10mg, 50mg and 100mg, **11)** Penciclovir cream 1%, **12)** Ribociclib, Letrozol tablets USP Co-pack, 200mg,2.5mg, **13)** Erythromycin lactobionate for injection USP, 500mg/vial, **14)** levothyroxine tablets, **15)** Lamotrigine ODT USP, **16)** Azithromycin for oral suspension USP, **17)** Valgancyclovir Oral solution, **18)** Difluprednate ophthalmic emulsion, 0.05%, **19)** Tacrolimus Ointment, 0.1%

Time horizon / Category of product launch	No. of Products	Comments / Details
YTD Approved BUT NOT Commercialized	<b>40</b>	<ul style="list-style-type: none"> <li>• <b>15</b> products not planned to be launched in near future: Pramipexole Dihydrochloride Tab, Metronidazole ER Tab, Quetiapine Fumarate Tab, Levetiracetam, METRONIDAZOLE 250 mg &amp; 500 mg, Glycopyrrolate Tab, Travoprost Ophthalmic Sol, Fenofibrate Tablets 54mg, 160mg, Testosterone Gel, 1.62% (Pump), Testosterone Topical Solution, 30mg/1.5mL, Nifedipine ER tablets, Albendazole tablets, Lamotrigine ER Tablets, Carbamazepine Tab, Travoprost Ophthalmic Solution USP, 0.004%</li> <li>• <b>1</b> Product not to be Re-launch on Alembic INC Label due to low price point: Duloxetine HCl DR Capsules</li> <li>• <b>6</b> Product to be launched in Q4'26: Doxorubicin Inj, Phytonadione Inj., Sumatriptan injection, Diltiazem HCl tablets, Loteprednol &amp; Tobramycin oph. Suspension, Dexlansoprazole DR capsules</li> <li>• <b>7</b> Product to be launched in Q1'27 – Diltiazem Hydrochloride Extended-Release Capsules, Divalproex Sodium DR Capsules, Carbamazepine ER Tablets, Dasatinib tablets, Triamcinolone acetonide inj, Macitentan Tablets, Bosutinib Tab</li> <li>• <b>7</b> Products to be launched subject to Technical &amp; COGS Feasibility: Carbidopa and Levodopa Extended-Release Tablets, Erythromycin tablets, Telmisartan and Amlodipine Tablets, Treprostinil Injection, Hydrochlorothiazide Capsules, Lithium Carbonate ER Tablets, Silodosin Capsules.</li> <li>• <b>1</b> Product launch to be decided – Paroxetine ER tablets</li> <li>• <b>3</b> Product Late launch as per settlement - Selexipag Tablets, Brexpiprazole tablets, Alcaftadine ophthalmic solution.</li> </ul>

Filing upto FY 25	140
Q1-FY25-26	0
Q2-FY25-26	1
Q3-FY25-26	2
Cumulative FY26	143

# Branded Formulations

## Q3 FY26

# Therapy-wise Performance – QTR

## Dec 25



Therapy	Q3 FY26					Q3 FY25				
	IPM Therapy Growth (ORG)	Market Share (ORG)	Alembic Growth (ORG)	Alembic Growth (PRIM)	RPM Therapy Growth (ORG)	Therapy Growth (ORG)	Market Share (ORG)	Alembic Growth (ORG)	Alembic Growth (PRIM)	RPM Therapy Growth (ORG)
Gynecology	13	3.4	15	11	12	5	3.4	7	2	6
Cardiology	17	1.5	9	3	18	12	1.6	8	11	13
Gastrology	8	1.1	-6	-9	9	7	1.2	3	8	11
Anti Diabetic	10	1.4	3	-1	9	8	1.5	15	8	13
Orthopaedic	9	0.6	-1	1	6	8	0.6	-8	-8	10
Nephro / Uro	14	1.1	-1	4	18	12	1.4	4	9	19
Ophthalmology	11	2.1	8	12	11	11	2.2	12	15	14
Dermatological	9	0.1	7	-1	14	11	0.1	12	33	15
<b>SPECIALTY</b>	<b>12</b>	<b>1.4</b>	<b>6</b>	<b>3</b>	<b>13</b>	<b>9</b>	<b>1.4</b>	<b>6</b>	<b>6</b>	<b>11</b>
Anti Infective	4	2.1	-2	2	-1	2	2.2	-12	-15	-6
OL			-1	5	-1			-4	-4	-1
OS			-2	2	-1			-14	-14	-7
Cough & Cold	4	4.2	-1	4	6	2	4.3	-3	-4	1
<b>ACUTE</b>	<b>4</b>	<b>2.6</b>	<b>1</b>	<b>2</b>	<b>4</b>	<b>2</b>	<b>2.7</b>	<b>-10</b>	<b>-11</b>	<b>0</b>
<b>OVERALL</b>	<b>12</b>	<b>1.2</b>	<b>4</b>	<b>6</b>	<b>12</b>	<b>8</b>	<b>1.3</b>	<b>0</b>	<b>3</b>	<b>8</b>

# Therapy-wise Revenue Performance and Contribution – QTR Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont.	Growth	Q3 FY25 (Rs. in Cr )	Cont.	Growth
Gynecology	83	13%	11%	75	12%	2%
Cardiology	78	12%	3%	76	12%	11%
Gastrology	60	9%	-9%	66	11%	8%
Anti Diabetic	38	6%	-1%	38	6%	7%
Orthopaedic	19	3%	1%	19	3%	-8%
Nephro / Uro	16	2%	4%	15	2%	9%
Ophthalmology	15	2%	12%	13	2%	15%
Vitamins and Tonics	11	2%	3%	11	2%	-1%
Dermatological	5	1%	-1%	5	1%	33%
<b>SPECIALTY</b>	<b>324</b>	<b>50%</b>	<b>3%</b>	<b>315</b>	<b>51%</b>	<b>6%</b>
Anti Infective	117	18%	2%	114	19%	-15%
Cough & Cold	69	11%	4%	66	11%	-4%
<b>ACUTE</b>	<b>186</b>	<b>28%</b>	<b>2%</b>	<b>182</b>	<b>30%</b>	<b>-11%</b>
<b>Animal Health</b>	<b>143</b>	<b>22%</b>	<b>22%</b>	<b>117</b>	<b>19%</b>	<b>23%</b>
<b>OVERALL</b>	<b>652</b>	<b>100%</b>	<b>6%</b>	<b>614</b>	<b>100%</b>	<b>3%</b>

# Gynecology Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>GYNEC</b>	<b>83</b>	<b>13%</b>	<b>11%</b>	<b>14%</b>	<b>75</b>	<b>12%</b>	<b>2%</b>	<b>6%</b>
CRINA-NCR	14	17%	8%	14%	13	17%	16%	5%
GESTOFIT	14	17%	7%	7%	13	17%	9%	4%
RICHAR-CR	10	12%	5%	5%	10	13%	-3%	7%
ISOFIT	10	12%	7%	13%	9	12%	25%	5%
LACTONIC	7	8%	14%	13%	6	8%	10%	3%
VEHYCAL - XT	4	5%	4%	21%	4	5%	8%	30%
ESTROPLUS	4	5%	11%	16%	4	5%	12%	17%
CYCLOSET	3	4%	18%	22%	3	4%	2%	5%
PROTINULES	2	3%	-9%	-1%	3	3%	-15%	-11%
ELATA	2	2%	-1%	-9%	2	2%	0%	-13%
OVIGYN	2	2%	229%	9%	0	1%	-91%	5%
CLOSTOP	2	2%	0%	11%	2	2%	4%	3%
FOLINAL	1	2%	-1%	12%	1	2%	-3%	-6%
VEHYCAL	1	1%	-14%	6%	1	1%	-14%	-29%
HARMONI	1	1%	-21%	14%	1	1%	12%	5%
RUMIGEST	1	1%	-20%	-4%	1	1%	-12%	9%
RICHGLOW	1	1%	-2%	-6%	1	1%	-3%	8%



# Cardiology Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>CARDIO</b>	<b>78</b>	<b>12%</b>	<b>3%</b>	<b>18%</b>	<b>76</b>	<b>12%</b>	<b>11%</b>	<b>13%</b>
TELLZY	26	33%	-10%	17%	29	38%	10%	11%
CETANIL	25	33%	15%	28%	22	29%	15%	19%
ROSAVE	15	19%	13%	21%	13	18%	6%	18%
TETAN	3	4%	-6%	14%	4	5%	-3%	8%
TELLZY ACH	2	2%	8%	18%	1	2%	15%	22%



# Gastrology Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>GASTRO</b>	<b>60</b>	<b>9%</b>	<b>-9%</b>	<b>9%</b>	<b>66</b>	<b>11%</b>	<b>8%</b>	<b>11%</b>
REKOOL	14	23%	-8%	4%	15	22%	-5%	0%
ULGEL	13	22%	2%	5%	13	19%	-2%	2%
DELTON	4	7%	-15%	17%	5	7%	-15%	5%
LIVFIT	3	5%	8%	13%	3	4%	10%	27%
FREEGO	3	5%	22%	21%	2	4%	-3%	47%
ULGERAFT	3	4%	-9%	8%	3	4%	9%	5%
ESOLEMBIC	2	4%	-9%	9%	3	4%	-6%	12%
PROBIOTICS	1	1%	-3%	7%	1	1%	-16%	1%
AL5ZYME	1	1%	-28%	9%	1	1%	-6%	16%
RAFLE	1	1%	-24%	10%	1	1%	-3%	15%
PIORIDE	1	1%	10%	21%	1	1%	-13%	47%



# Anti Diabetic Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>ANTIDIABETIC</b>	<b>38</b>	<b>6%</b>	<b>-1%</b>	<b>9%</b>	<b>38</b>	<b>6%</b>	<b>7%</b>	<b>13%</b>
VOAGE	6	17%	-11%	19%	7	18%	23%	44%
GLISEN	5	13%	-21%	9%	6	16%	15%	6%
SITALEMBIC	6	15%	21%	20%	5	12%	53%	29%
GLZ	5	14%	1%	15%	5	14%	-2%	11%
GLIPY	5	14%	2%	2%	5	13%	0%	0%
VILDAMBIC	3	9%	13%	3%	3	8%	24%	-2%
VOGO	3	8%	6%	4%	3	7%	-7%	3%
TRIVOGO	2	4%	4%	3%	2	4%	-6%	5%
DONANCE	1	3%	64%	14%	1	2%	-7%	29%



# Anti infective Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>ANTI INFECTIVE</b>	<b>117</b>	<b>18%</b>	<b>2%</b>	<b>-1%</b>	<b>114</b>	<b>19%</b>	<b>-15%</b>	<b>-6%</b>
AZITHRAL	78	67%	7%	-1%	73	64%	-17%	-9%
ALTHROCIN	20	17%	-8%	-13%	22	19%	5%	-1%
ROXID	10	9%	1%	-4%	10	9%	-13%	-8%
CLOFF	6	5%	-2%	9%	6	5%	5%	9%
VITARESP	3	2%	5%	11%	3	2%	1%	3%



# Cough & Cold Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>COUGH &amp; COLD</b>	<b>69</b>	<b>11%</b>	<b>4%</b>	<b>0%</b>	<b>66</b>	<b>11%</b>	<b>-4%</b>	<b>0%</b>
WIKORYL	25	36%	-2%	2%	25	38%	5%	1%
LAVETA	13	19%	8%	15%	12	19%	-2%	3%
BROZEET-LS	14	20%	12%	11%	12	19%	1%	5%
ZEET	6	8%	10%	2%	5	8%	-22%	2%
BROZEET	4	5%	0%	1%	4	6%	-19%	-7%
BILAMBIC-M	3	4%	6%	24%	3	4%	0%	4%
EPHEDREX	1	1%	-15%	7%	1	1%	-20%	-1%



# Anti Diabetic Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>ANTIDIABETIC</b>	<b>38</b>	<b>6%</b>	<b>-1%</b>	<b>9%</b>	<b>38</b>	<b>6%</b>	<b>7%</b>	<b>13%</b>
VOAGE	6	17%	-11%	19%	7	18%	23%	44%
GLISEN	5	13%	-21%	9%	6	16%	15%	6%
SITALEMBIC	6	15%	21%	20%	5	12%	53%	29%
GLZ	5	14%	1%	15%	5	14%	-2%	11%
GLIPY	5	14%	2%	2%	5	13%	0%	0%
VILDAMBIC	3	9%	13%	3%	3	8%	24%	-2%
VOGO	3	8%	6%	4%	3	7%	-7%	3%
TRIVOGO	2	4%	4%	3%	2	4%	-6%	5%
DONANCE	1	3%	64%	14%	1	2%	-7%	29%



# Anti infective Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>ANTI INFECTIVE</b>	<b>117</b>	<b>18%</b>	<b>2%</b>	<b>-1%</b>	<b>114</b>	<b>19%</b>	<b>-15%</b>	<b>-6%</b>
AZITHRAL	78	67%	7%	-1%	73	64%	-17%	-9%
ALTHROCIN	20	17%	-8%	-13%	22	19%	5%	-1%
ROXID	10	9%	1%	-4%	10	9%	-13%	-8%
CLOFF	6	5%	-2%	9%	6	5%	5%	9%
VITARESP	3	2%	5%	11%	3	2%	1%	3%



# Cough & Cold Performance – QTR

## Dec 25

Therapy	Q3 FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	Q3 FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>COUGH &amp; COLD</b>	<b>69</b>	<b>11%</b>	<b>4%</b>	<b>0%</b>	<b>66</b>	<b>11%</b>	<b>-4%</b>	<b>0%</b>
WIKORYL	25	36%	-2%	2%	25	38%	5%	1%
LAVETA	13	19%	8%	15%	12	19%	-2%	3%
BROZEET-LS	14	20%	12%	11%	12	19%	1%	5%
ZEET	6	8%	10%	2%	5	8%	-22%	2%
BROZEET	4	5%	0%	1%	4	6%	-19%	-7%
BILAMBIC-M	3	4%	6%	24%	3	4%	0%	4%
EPHEDREX	1	1%	-15%	7%	1	1%	-20%	-1%



# Therapy-wise Performance – 9M FY26



Therapy	9M FY26					9M FY25				
	IPM Therapy Growth (ORG)	Market Share (ORG)	Alembic Growth (ORG)	Alembic Growth (PRIM)	RPM Therapy Growth (ORG)	Therapy Growth (ORG)	Market Share (ORG)	Alembic Growth (ORG)	Alembic Growth (PRIM)	RPM Therapy Growth (ORG)
Gynecology	9	3.4	16	7	9	6	3.3	12	6	7
Cardiology	14	1.5	6	4	15	12	1.6	9	11	14
Gastrology	6	1.0	-9	-11	8	10	1.2	8	9	11
Anti Diabetic	6	1.4	2	0	7	8	1.5	18	9	14
Orthopaedic	6	0.6	-3	-2	6	8	0.6	-6	-5	11
Nephro / Uro	11	1.2	1	4	16	11	1.4	-1	4	18
Ophthalmology	9	2.1	4	9	8	3	2.2	17	17	6
Dermatological	6	0.1	7	-6	11	10	0.1	10	6	14
<b>SPECIALTY</b>	<b>8</b>	<b>1.4</b>	<b>3</b>	<b>1</b>	<b>10</b>	<b>9</b>	<b>1.4</b>	<b>8</b>	<b>7</b>	<b>11</b>
Anti Infective	5	2.0	0	2	3	5	2.0	-5	-7	-3
OL			0	4	5			1	0	-1
OS			0	1	3			-7	-8	-3
Cough & Cold	10	4.2	7	10	13	-2	4.3	-5	-2	-3
<b>ACUTE</b>	<b>6</b>	<b>2.4</b>	<b>5</b>	<b>5</b>	<b>10</b>	<b>4</b>	<b>2.4</b>	<b>-6</b>	<b>-5</b>	<b>-2</b>
<b>OVERALL</b>	<b>9</b>	<b>1.1</b>	<b>4</b>	<b>5</b>	<b>10</b>	<b>8</b>	<b>1.2</b>	<b>3</b>	<b>6</b>	<b>9</b>

# Therapy-wise Revenue Performance and Contribution – 9M FY26

Therapy	9M FY26 (Rs. in Cr )	Cont.	Growth	9M FY25 (Rs. in Cr )	Cont.	Growth
Gynecology	256	14%	7%	239	13%	6%
Cardiology	244	13%	4%	234	13%	11%
Gastrology	181	10%	-11%	202	11%	9%
Anti Diabetic	120	6%	0%	120	7%	9%
Orthopaedic	58	3%	-2%	60	3%	-5%
Nephro / Uro	46	2%	4%	44	2%	4%
Ophthalmology	43	2%	9%	40	2%	17%
Vitamins and Tonics	31	2%	4%	30	2%	-4%
Dermatological	14	1%	-6%	15	1%	6%
<b>SPECIALTY</b>	<b>993</b>	<b>53%</b>	<b>1%</b>	<b>983</b>	<b>55%</b>	<b>7%</b>
Anti Infective	333	18%	2%	325	18%	-7%
Cough & Cold	169	9%	10%	153	9%	-2%
<b>ACUTE</b>	<b>502</b>	<b>27%</b>	<b>5%</b>	<b>479</b>	<b>27%</b>	<b>-5%</b>
<b>Animal Health</b>	<b>395</b>	<b>21%</b>	<b>19%</b>	<b>332</b>	<b>19%</b>	<b>22%</b>
<b>OVERALL</b>	<b>1,890</b>	<b>100%</b>	<b>5%</b>	<b>1,795</b>	<b>100%</b>	<b>6%</b>

# Gynecology Performance – 9M FY25

Therapy	9M FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	9M FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>GYNEC</b>	<b>256</b>	<b>14%</b>	<b>7%</b>	<b>9%</b>	<b>239</b>	<b>13%</b>	<b>6%</b>	<b>7%</b>
CRINA-NCR	44	17%	12%	10%	39	16%	19%	6%
GESTOFIT	43	17%	12%	10%	39	16%	3%	3%
RICHAR-CR	33	13%	6%	7%	31	13%	10%	6%
ISOFIT	31	12%	8%	9%	29	12%	27%	8%
LACTONIC	19	7%	7%	9%	18	7%	9%	9%
VEHYCAL - XT	14	5%	2%	21%	13	6%	13%	31%
ESTROPLUS	12	5%	12%	15%	11	5%	11%	18%
CYCLOSET	10	4%	13%	14%	9	4%	5%	5%
PROTINULES	8	3%	-9%	-5%	9	4%	-15%	-11%
ELATA	6	2%	1%	-10%	6	2%	-4%	-12%
CLOSTOP	5	2%	5%	7%	5	2%	6%	5%
FOLINAL	4	2%	3%	6%	4	2%	-6%	7%
VEHYCAL	3	1%	-12%	5%	4	1%	-18%	-2%
OVIGYN	3	1%	-49%	-10%	7	3%	-56%	-13%
HARMONI	2	1%	-23%	6%	3	1%	7%	9%
RUMIGEST	2	1%	-23%	-11%	3	1%	0%	11%
RICHGLOW	2	1%	-9%	-8%	2	1%	-1%	11%



# Cardiology Performance – 9M FY26

Therapy	9M FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	9M FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>CARDIO</b>	<b>244</b>	<b>13%</b>	<b>4%</b>	<b>15%</b>	<b>234</b>	<b>13%</b>	<b>11%</b>	<b>14%</b>
TELLZY	86	35%	-5%	14%	91	39%	12%	13%
CETANIL	77	32%	15%	22%	67	29%	18%	22%
ROSAVE	46	19%	13%	21%	40	17%	6%	18%
TETAN	11	4%	-9%	12%	12	5%	1%	11%
TELLZY ACH	4	2%	9%	16%	4	2%	15%	23%
TACKEL	1	0%	-4%	20%	1	0%	-16%	17%



# Gastrology Performance – 9M FY26

Therapy	9M FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	9M FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>GASTRO</b>	<b>181</b>	<b>10%</b>	<b>-11%</b>	<b>8%</b>	<b>202</b>	<b>11%</b>	<b>9%</b>	<b>11%</b>
REKOOL	40	22%	-15%	0%	47	23%	-2%	2%
ULGEL	40	22%	-5%	0%	42	21%	3%	5%
DELTON	12	7%	-25%	12%	16	8%	-1%	9%
ESOLEMBIC	9	5%	12%	12%	8	4%	19%	31%
ULGERAFT	9	5%	7%	23%	8	4%	15%	56%
LIVFIT	9	5%	-5%	2%	9	5%	1%	8%
FREEGO	8	4%	-15%	8%	10	5%	14%	12%
AL5ZYME	3	2%	-9%	2%	4	2%	-10%	5%
PROBIOTICS	2	1%	-21%	5%	3	1%	-1%	17%
RAFLE	2	1%	-29%	8%	3	2%	-1%	14%
PIORIDE	2	1%	-21%	11%	2	1%	-7%	13%
EXCERAFT	2	1%	-7%	23%	2	1%	6%	56%
LEVOGASTROL	1	1%	-9%	-9%	2	1%	-9%	-4%



# Anti Diabetic Performance – 9M FY26

Therapy	9M FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	9M FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>ANTIDIABETIC</b>	<b>120</b>	<b>6%</b>	<b>0%</b>	<b>7%</b>	<b>120</b>	<b>7%</b>	<b>9%</b>	<b>14%</b>
VOAGE	21	18%	-5%	-4%	22	18%	24%	7%
SITALEMBIC	17	15%	25%	16%	14	12%	56%	32%
GLZ	17	14%	1%	12%	17	14%	-2%	11%
GLIPY	16	13%	-2%	-2%	16	14%	4%	2%
GLISEN	16	13%	-19%	6%	19	16%	11%	6%
VILDAMBIC	10	9%	14%	-1%	9	8%	27%	-1%
VOGO	9	8%	5%	1%	9	7%	-9%	3%
TRIVOGO	5	4%	1%	1%	5	4%	-6%	5%
DONANCE	3	3%	55%	13%	2	2%	66%	31%
ETERNEX	2	2%	-36%	-14%	3	3%	-15%	-16%



# Anti infective Performance – 9M FY26

Therapy	9M FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	9M FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>ANTI INFECTIVE</b>	<b>333</b>	<b>18%</b>	<b>2%</b>	<b>3%</b>	<b>325</b>	<b>18%</b>	<b>-7%</b>	<b>-3%</b>
AZITHRAL	210	63%	6%	3%	199	61%	-10%	-10%
ALTHROCIN	65	19%	-6%	-12%	69	21%	7%	7%
ROXID	28	8%	-4%	-2%	29	9%	-4%	-4%
CLOFF	16	5%	12%	15%	14	4%	3%	3%
VITARESP	7	2%	7%	8%	6	2%	8%	8%



# Cough & Cold Performance – 9M FY26

Therapy	9M FY26 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG	9M FY25 (Rs. in Cr )	Cont %	Growth % PRIM	Therapy Growth% ORG
<b>COUGH &amp; COLD</b>	<b>169</b>	<b>9%</b>	<b>10%</b>	<b>13%</b>	<b>153</b>	<b>9%</b>	<b>-2%</b>	<b>-3%</b>
WIKORYL	65	38%	9%	7%	59	39%	4%	0%
LAVETA	33	20%	6%	13%	32	21%	1%	3%
BROZEET-LS	31	18%	20%	21%	26	17%	-2%	-1%
ZEET	14	8%	16%	11%	12	8%	-17%	1%
BROZEET	8	5%	3%	8%	8	5%	-13%	-8%
BILAMBIC-M	8	5%	11%	20%	7	5%	0%	7%
EPHEDREX	2	1%	-2%	13%	2	1%	-21%	-6%
NAZOBIC	1	1%	-11%	13%	1	1%	-20%	7%



# DIVISION WISE PCPM Q1,Q2,Q3 FY26

Division	MR*	Q1 FY26	PCPM	Q2 FY26	PCPM CY	Q3 FY26	PCPM CY
		(Rs. In Cr)	(Rs. In lakhs)	(Rs. In Cr)	(Rs. In lakhs)	(Rs. In Cr)	(Rs. In lakhs)
MEGACARE	580	70	4.0	83	4.8	88	5.1
MAXIS	545	51	3.1	70	4.3	71	4.3
PHARMA	417	29	2.3	35	2.8	35	2.8
SUMMIT	364	36	3.3	30	2.8	30	2.8
CARDIGEM	253	15	2.0	12	1.6	11	1.5
CORAZON	271	24	3.0	24	3.0	25	3.1
SPECIA	368	38	3.4	36	3.3	37	3.4
OURON	173	15	2.9	15	2.9	16	3.0
GASTRON	176	10	1.9	10	1.9	9	1.8
ZENOVI	296	26	2.9	26	2.9	26	2.9
ALCARE	293	22	2.5	22	2.5	21	2.4
ELENA	313	41	4.4	40	4.3	41	4.3
EYECARE	169	15	3.0	14	2.7	15	2.9
ENTERON	459	34	2.5	36	2.6	35	2.6
OSTEOFIT	169	13	2.6	11	2.3	11	2.2
CORIUM	98	5	1.7	5	1.6	6	2.0
VETMAX	300	35	3.9	53	5.9	51	5.7
FARMCURE	300	47	5.2	57	6.3	60	6.7
POULTRY	101	28	9.2	23	7.7	28	9.1
PETAL	64	4	2.1	4	2.3	4	2.3
<b>Branded</b>	<b>5,839</b>	<b>603</b>	<b>3.5</b>	<b>644</b>	<b>3.8</b>	<b>659</b>	<b>3.8</b>

\*No of MR considered based on count approved as on FY 25-26

# DIVISION WISE PCPM Q1 & Q2 FY26



Division	MR*	9M FY26	PCPM CY	MR*	9M FY25	PCPM CY	Growth
		(Rs. In Cr)	(Rs. In lakhs)		(Rs. In Cr)	(Rs. In lakhs)	
MEGACARE	580	242	4.6	581	237	4.5	2%
MAXIS	545	192	3.9	538	188	3.9	1%
PHARMA	417	98	2.6	414	98	2.6	0%
ALGROW	139	25	2.0	0	10	-	100%
SUMMIT	364	97	3.0	333	99	3.3	-10%
CARDIGEM	253	38	1.7	275	46	1.9	-12%
CORAZON	271	74	3.0	271	69	2.8	7%
SPECIA	368	111	3.4	289	100	3.8	-12%
OURON	173	46	3.0	176	44	2.8	6%
GASTRON	176	29	1.8	175	37	2.4	-22%
ZENOVI	296	78	2.9	295	75	2.8	4%
ALCARE	293	66	2.5	288	63	2.4	3%
ELENA	313	122	4.3	302	114	4.2	3%
EYECARE	169	43	2.8	169	39	2.6	11%
ENTERON	459	106	2.6	457	116	2.8	-9%
OSTEOFIT	169	35	2.3	169	37	2.4	-5%
CORIUM	98	16	1.8	94	15	1.8	-1%
VETMAX	300	139	5.2	300	117	4.3	19%
FARMCURE	300	164	6.1	300	140	5.2	17%
POULTRY	101	79	8.7	101	69	7.6	15%
PETAL	64	13	2.3	64	8	1.4	58%
<b>Branded</b>	<b>5,848</b>	<b>1,828</b>	<b>3.5</b>	<b>5,712</b>	<b>1,737</b>	<b>3.4</b>	<b>3%</b>

# Growth % Break up MAT Dec 25



Company	MAT Dec 25				MAT Dec 24				MAT Dec 23			
	Value Growth %	Volume Grth %	Price Grth %	New Prod Grth %	Value Growth %	Volume Grth %	Price Grth %	New Prod Grth %	Value Growth %	Volume Grth %	Price Grth %	New Prod Grth %
IPM	8.9	2.1	4.3	2.5	7.7	0.5	4.6	2.6	9.7	1.8	5.0	3.0
Alembic	0.5	-6.1	4.9	1.7	0.8	-6.9	5.4	2.2	8.6	-1.3	5.6	4.2

## New Product Launched:

- Launched 4 new brands in the domestic market Q3 FY25 and 9 in 9M FY26 with contribution of 2.4% of total branded sales for 9M FY26.
- 13% of the product portfolio is part of NLEM

# New Launches in last 24 months



Materic	Division	SKU name	Month	Brand	Period	Rs in crores		
						Q3 FY2	9M FY2	Mat De
50002386	Gastron	TOFAZIFF 5MG 10 TABS	Jan-24	Tofaziff	Q4 FY24	0.02	0.02	0.06
50002387	Gastron	TOFAZIFF 5MG 30 TABS	Jan-24	Tofaziff	Q4 FY24	(0.01)	(0.01)	0.01
50002388	Gastron	TOFAZIFF 11 XR 10 TABS	Jan-24	Tofaziff	Q4 FY24	0.07	0.17	0.23
50000387	Alcare	GESTOFIT CAPSULES 300 MG 10'S	Jan-24	Gestofit	Q4 FY24	0.16	0.55	0.67
50002427	Alcare	EVARAFT 150ML SUSPENSION	Feb-24	Evaraft	Q4 FY24	(0.02)	1.25	2.07
50002334	Elena	ISOFIT SR 30 MG TABLET 10'S	Mar-24	Isofit	Q4 FY24	0.53	1.65	2.14
50002425	Gastron	FREGGO SYRUP 250ML	Mar-24	Freego	Q4 FY24	0.23	0.72	0.95
50002333	Elena	ISOFIT SR 20 MG TABLET 10'S	Jun-24	Isofit	Q1 FY25	2.18	6.57	8.11
50002423	Corium	ORYZA AD CREAM 30GM	Apr-24	Oryza AD	Q1 FY25	(0.01)	0.02	0.04
50002426	Corium	ORYZA AD CREAM 10GM	Apr-24	Oryza AD	Q1 FY25	(0.00)	0.00	0.01
50002431	Osteofit	TOFALEMBIC OD 11MG 14 TABS	May-24	Tofalembic	Q1 FY25	(0.01)	(0.01)	0.03
50002476	Enteron	VONOFIDE 10 TAB 10'S	Jun-24	Vonofide	Q1 FY25	0.07	0.25	-0.40
50002477	Enteron	VONOFIDE 20 TAB 10'S	Jun-24	Vonofide	Q1 FY25	0.67	2.20	0.21
50002478	Gastron	MONOVONO 10 TAB 10'S	Jun-24	Monovono	Q1 FY25	0.02	0.09	-0.33
50002479	Gastron	MONOVONO 20 TAB 10'S	Jun-24	Monovono	Q1 FY25	0.23	0.78	-0.34
50002435	Corium	JAKBIC 5MG 14'S TAB	Jul-24	Jakbic	Q2 FY25	0.01	0.07	0.10
50002436	Corium	JAKBIC XR 11MG 14'S TAB	Jul-24	Jakbic	Q2 FY25	(0.00)	0.04	0.07
50002453	Ouron	BLADSOL 5MG TABS	Aug-24	Bladsol	Q2 FY25	0.08	0.24	0.30
50002457	Cardigem	GLISEN SM 1 TABS 15'S	Sep-24	Glisen SM	Q2 FY25	0.17	0.49	0.59
50002458	Cardigem	GLISEN SM 2 TABS 15'S	Sep-24	Glisen SM	Q2 FY25	0.20	0.56	0.66
50002492	Corium	Oryza Ceramax 3:1:1 mois lotion 250m	Oct-24	Oryza	Q3 FY25	0.66	1.51	2.04
50002506	Specia	VOAGE L 10'S TAB	Oct-24	Voage L	Q3 FY25	0.12	0.39	0.52
50002445	Ouron	GERIPOD M 25MG TABS	Nov-24	Geripod	Q3 FY25	0.09	0.25	0.34
50002446	Ouron	GERIPOD M 50MG TABS	Nov-24	Geripod	Q3 FY25	0.24	0.68	0.85
50002514	Summit	VOAGE GM 1MG 10S TABS	Jan-25	Voage GM	Q4 FY25	0.04	0.09	0.32
50002515	Summit	VOAGE GM 2MG 10S TABS	Jan-25	Voage GM	Q4 FY25	0.06	0.15	0.38
50002516	Alcare	UNIGOLIX 150MG 10S TABS	Jan-25	Unigolix	Q4 FY25	1.06	3.01	3.58
50002517	Alcare	UNIGOLIX 200MG 10S TABS	Jan-25	Unigolix	Q4 FY25	0.63	1.78	2.33
50002501	Eyecare	TRAVISIGHT PF 5ML	Feb-25	Travisight	Q4 FY25	0.12	0.33	0.49
50002505	Eyecare	RESYNC ULTRA 10ML EYE DROPS	Mar-25	Resync	Q4 FY25	0.28	0.81	0.91
40018854	Summit	TELLZY LN 40MG 15 TAB	Apr-25	Tellzy	Q1 FY26	0.52	1.83	1.83
40018855	Summit	TELLZY LN 80MG 10 TAB	Apr-25	Tellzy	Q1 FY26	0.06	0.34	0.34
50002504	Eyecare	PEGTEARS HP EYEDROP 10ML	Apr-25	Pegtears	Q1 FY26	0.79	2.32	2.32
50002495	Corium	GROGAIN PRO ADV HAIR GROWTH SER	Apr-25	Grogain	Q1 FY26	0.61	1.67	1.67
50002494	Corium	GROGAIN MF 60ML	Jun-25	Grogain	Q1 FY26	0.13	0.40	0.40
50002553	Pharma	DONANCE S PRO 500 10'S TABS	Jul-25	Donance S	Q2 FY26	0.29	0.63	0.63
50002554	Pharma	DONANCE S PRO 1000 10'S TABS	Jul-25	Donance S	Q2 FY26	0.07	0.20	0.20
50002556	Maxis	ZEET LD 120ML SYRUP	Jul-25	Zeet LD	Q2 FY26	0.61	1.60	1.60
50002490	Corium	ORYZA ACNE CREAM 75GM	Oct-25	Oryza	Q3 FY26	0.26	0.26	0.26
50002570	Cardigem	GLISEN SM 1-50-500 10'S TABS	Nov-25	Glisen SM	Q3 FY26	0.09	0.09	0.09
50002571	Cardigem	GLISEN SM 2-50-500 10'S TABS	Nov-25	Glisen SM	Q3 FY26	0.10	0.10	0.10
50002555	Elena	COQBLOOM 300MG 15'S CAPS	Nov-25	Coqbloom	Q3 FY26	1.44	1.44	1.44
50002584	Zenovi	OVIGYN Q10 TABLETS 10S	Dec-25	Ovigyn	Q3 FY26	0.66	0.66	0.66
		<b>Total Branded</b>				<b>13.55</b>	<b>36.19</b>	<b>38.49</b>

# TOP 20 BRANDS



BRANDS	Rank MAT Dec 25	Q3 FY 26	Q3 FY 25	GR %	Q2 FY 26	Q2 FY 25	GR %	Q1 FY 26	Q1 FY 25	GR %	Q4 FY 25	Q4 FY 24	GR %	MAT Dec 25	MAT Dec 24	GR %
<b>AZITHRAL</b>	<b>1</b>	116	114	<b>1.7</b>	109	104	<b>4.7</b>	95	91	<b>4.3</b>	101	109	<b>-7.0</b>	421	418	<b>0.8</b>
J01F04 AZITHROMYCIN		365	369	<b>-1.2</b>	362	351	<b>3.3</b>	278	258	<b>7.8</b>	321	338	<b>-5.2</b>	1,326	1,316	<b>0.7</b>
<b>TELLZY</b>	<b>6</b>	59	58	<b>1.4</b>	55	58	<b>-4.3</b>	61	60	<b>2.0</b>	55	55	<b>-0.8</b>	230	231	<b>-0.4</b>
C02C04 TELMISARTAN		1,759	1,504	<b>17.0</b>	1,657	1,475	<b>12.3</b>	1,685	1,474	<b>14.4</b>	1,401	1,286	<b>8.9</b>	6,502	5,739	<b>13.3</b>
<b>WIKORYL</b>	<b>3</b>	47	47	<b>-1.3</b>	42	36	<b>16.6</b>	30	27	<b>12.1</b>	42	41	<b>3.7</b>	161	151	<b>6.7</b>
R05A01 COLD PREP.		448	448	<b>0.0</b>	404	364	<b>11.0</b>	287	257	<b>11.7</b>	387	391	<b>-1.0</b>	1,526	1,460	<b>4.5</b>
<b>ALTHROCIN</b>	<b>1</b>	29	34	<b>-14.2</b>	32	39	<b>-18.8</b>	30	31	<b>-4.5</b>	27	29	<b>-7.3</b>	117	133	<b>-11.8</b>
J01F01 ERYTHROMYCIN		33	39	<b>-13.4</b>	37	45	<b>-18.4</b>	33	35	<b>-3.6</b>	31	32	<b>-4.6</b>	135	151	<b>-10.8</b>
<b>REKOOL</b>	<b>7</b>	22	25	<b>-9.5</b>	23	27	<b>-15.5</b>	23	26	<b>-13.4</b>	22	25	<b>-11.7</b>	89	102	<b>-12.6</b>
A02B0F RABEPRAZOLE		513	494	<b>3.9</b>	528	541	<b>-2.3</b>	516	518	<b>-0.3</b>	465	473	<b>-1.7</b>	2,022	2,025	<b>-0.2</b>
<b>CETANIL</b>	<b>2</b>	44	36	<b>22.4</b>	40	35	<b>13.9</b>	40	35	<b>15.8</b>	36	32	<b>11.7</b>	160	138	<b>16.1</b>
C01D0B CILNIDIPINE		623	488	<b>27.7</b>	574	482	<b>19.2</b>	554	465	<b>19.2</b>	515	437	<b>17.9</b>	2,266	1,871	<b>21.1</b>
<b>ULGEL</b>	<b>4</b>	22	22	<b>-3.0</b>	23	25	<b>-8.0</b>	21	24	<b>-14.1</b>	19	20	<b>-8.4</b>	84	91	<b>-8.5</b>
A02A05 ANTACID+ANTIPLATU.		360	331	<b>8.8</b>	376	365	<b>3.0</b>	319	308	<b>3.7</b>	202	199	<b>1.6</b>	1,257	1,203	<b>4.5</b>
<b>GESTOFIT SR</b>	<b>2</b>	27	26	<b>6.5</b>	28	26	<b>10.1</b>	31	28	<b>9.8</b>	27	26	<b>6.0</b>	114	105	<b>8.1</b>
G03D03 PROGESTERONE-SR		255	226	<b>13.1</b>	255	232	<b>9.8</b>	269	245	<b>9.8</b>	242	228	<b>6.2</b>	1,021	931	<b>9.7</b>
<b>ROSAVE</b>	<b>9</b>	23	20	<b>13.9</b>	22	20	<b>7.3</b>	22	20	<b>10.7</b>	20	19	<b>4.1</b>	87	79	<b>9.1</b>
C10A04 ROSUVASTATIN		1,055	884	<b>19.3</b>	987	873	<b>13.1</b>	982	849	<b>15.6</b>	890	787	<b>13.1</b>	3,914	3,393	<b>15.3</b>
<b>ROXID</b>	<b>1</b>	16	17	<b>-4.6</b>	16	16	<b>0.5</b>	14	14	<b>0.0</b>	17	18	<b>-4.2</b>	63	64	<b>-2.3</b>
J01F07 ROXITHROMYCIN		17	18	<b>-4.6</b>	16	16	<b>-0.3</b>	15	15	<b>-0.4</b>	18	19	<b>-4.2</b>	66	68	<b>-2.5</b>
<b>ZEET</b>	<b>13</b>	10	10	<b>7.5</b>	14	13	<b>11.1</b>	9	9	<b>-0.8</b>	15	17	<b>-14.7</b>	48	49	<b>-1.0</b>
R05B01 COUGH PREP		547	534	<b>2.3</b>	622	541	<b>15.0</b>	415	356	<b>16.5</b>	687	684	<b>0.5</b>	2,272	2,115	<b>7.4</b>

**\*Above ranks are based on respective Molecule group**

# TOP 20 BRANDS



BRANDS	Rank MAT Dec 25	Q3 FY 26	Q3 FY 25	GR %	Q2 FY 26	Q2 FY 25	GR %	Q1 FY 26	Q1 FY 25	GR %	Q4 FY 25	Q4 FY 24	GR %	MAT Dec 25	MAT Dec 24	GR %
<b>CRINA-NCR</b>	<b>1</b>	25	22	<b>12.1</b>	25	22	<b>12.3</b>	25	22	<b>12.3</b>	21	19	<b>14.7</b>	96	85	<b>12.8</b>
G03D02 NORETHISTERONE		85	79	<b>7.0</b>	84	75	<b>11.7</b>	85	76	<b>12.1</b>	79	70	<b>13.4</b>	333	300	<b>11.0</b>
<b>LAVETA</b>	<b>8</b>	16	17	<b>-2.4</b>	13	13	<b>3.0</b>	12	11	<b>5.0</b>	15	15	<b>-3.3</b>	56	56	<b>0.1</b>
R06A0D LEVOCETIRIZINE		532	453	<b>17.4</b>	428	376	<b>13.8</b>	344	300	<b>14.4</b>	417	404	<b>3.2</b>	1,721	1,534	<b>12.2</b>
<b>RICHAR</b>	<b>3</b>	19	17	<b>8.0</b>	19	19	<b>4.6</b>	20	19	<b>7.5</b>	16	17	<b>-5.7</b>	75	72	<b>3.7</b>
B03A01 CONV.IRON		147	140	<b>5.4</b>	215	202	<b>6.1</b>	225	203	<b>10.7</b>	791	760	<b>4.1</b>	1,378	1,305	<b>5.6</b>
<b>BROZEET-LS</b>	<b>3</b>	24	24	<b>3.2</b>	20	16	<b>28.1</b>	12	11	<b>7.2</b>	20	22	<b>-7.0</b>	77	72	<b>6.1</b>
R05B05 LEVOSALBUTAMOL & COMB.		386	348	<b>10.8</b>	299	221	<b>35.2</b>	189	155	<b>22.2</b>	307	296	<b>3.7</b>	1,182	1,021	<b>15.8</b>
<b>HERMIN</b>	<b>4</b>	12	12	<b>6.3</b>	13	12	<b>8.1</b>	13	12	<b>4.3</b>	10	11	<b>-7.5</b>	48	47	<b>3.1</b>
V06B03 PROTEIN,OTH.SUPPL.INJECT.		111	103	<b>7.3</b>	124	114	<b>8.8</b>	113	108	<b>4.4</b>	147	131	<b>12.4</b>	495	457	<b>8.4</b>
<b>LACTONIC GRAN</b>	<b>2</b>	12	10	<b>12.9</b>	10	10	<b>-0.4</b>	10	9	<b>2.6</b>	9	9	<b>-0.2</b>	40	39	<b>3.9</b>
LACTONIC GRAN MKT		49	43	<b>15.0</b>	41	41	<b>-0.6</b>	41	40	<b>3.4</b>	22	21	<b>5.7</b>	153	145	<b>6.1</b>
<b>ISOFIT</b>	<b>3</b>	22	18	<b>18.6</b>	22	19	<b>18.7</b>	23	19	<b>21.0</b>	20	16	<b>28.9</b>	87	72	<b>21.5</b>
G03D04 DYDROGESTERONE		341	302	<b>12.9</b>	338	319	<b>5.9</b>	360	333	<b>8.0</b>	327	304	<b>7.5</b>	1,365	1,258	<b>8.5</b>
<b>VOAGE</b>	<b>15</b>	12	12	<b>-0.8</b>	12	12	<b>-2.2</b>	13	12	<b>4.0</b>	12	10	<b>15.7</b>	48	47	<b>3.6</b>
A10B12 DAPAGLIFLOZIN		645	582	<b>10.9</b>	620	579	<b>7.2</b>	623	541	<b>15.0</b>	607	490	<b>23.9</b>	2,495	2,191	<b>13.8</b>
<b>VEHYCAL</b>	<b>10</b>	9	9	<b>-5.8</b>	9	10	<b>-9.0</b>	9	10	<b>-6.4</b>	8	8	<b>1.6</b>	36	38	<b>-5.2</b>
A12A01 CALCIUM ORAL SOLIDS		577	504	<b>14.5</b>	586	546	<b>7.3</b>	566	529	<b>6.9</b>	475	474	<b>0.3</b>	2,204	2,053	<b>7.4</b>
<b>ETRIK</b>	<b>4</b>	10	9	<b>5.2</b>	9	9	<b>-2.9</b>	9	9	<b>0.4</b>	9	8	<b>1.6</b>	37	36	<b>1.0</b>
M01A0Y ETORECOXIB ORAL SOLIDS		184	173	<b>6.4</b>	185	177	<b>4.4</b>	187	171	<b>9.5</b>	171	153	<b>11.9</b>	728	674	<b>7.9</b>
<b>GLIPY</b>	<b>10</b>	9	9	<b>-2.0</b>	9	9	<b>-5.9</b>	9	9	<b>-6.0</b>	8	8	<b>-2.2</b>	36	32	<b>12.9</b>
A10B0D METFORMIN + VILDAGLIPTIN		380	374	<b>1.5</b>	372	388	<b>-4.0</b>	379	388	<b>-2.4</b>	361	362	<b>-0.3</b>	1,511	1,493	<b>1.2</b>

**\*Above ranks are based on respective Molecule group**

*THANK YOU*